ArticleJournal of oncology practice2011
Off-label use of rituximab in a multipayer insurance system.
Article in Journal of oncology practice, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Indications for Rituximab Use in an Integrated Health Care Delivery System.Journal of managed care & specialty pharmacy · 2020Observational
- Computerized Approach to Creating a Systematic Ontology of Hematology/Oncology Regimens.JCO clinical cancer informatics · 2018Article
- Off-label use of targeted therapies in oncology.World journal of clinical oncology · 2016Review
- The diffusion of docetaxel in patients with metastatic prostate cancer.Journal of the National Cancer Institute · 2015Article
- Available evidence and outcome of off-label use of rituximab in clinical practice.European journal of clinical pharmacology · 2013Article
- Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Article
- Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective.Critical care (London, England) · 2012Review
- Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment.Immunology letters · 2012Review
- Review
- The Profile of Use of Rituximab in Tertiary Care Hospitals of Central India.Journal of pharmacy & bioallied sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOff-label prescribing in oncology is common and unregulated. The aim of this study was to describe the off-label use of rituximab, a novel anti-CD20 antibody, among patients from a large proprietary insurance database to understand how frequently and appropriately off-label prescribing occurs for this medication. PATIENTS AND
methodsIn this descriptive study, 11,232,642 patients were enrolled in the D2 Hawkeye commercial insurance database between 2001 and 2007, and 2,782 patients received rituximab. The main outcome measures were quantity and type of off-label usage, and expenditures for off-label usage.
resultsSeven hundred five (25.3%) patients received rituximab for off-label indications, and of those, 332 (47.1%) received rituximab for uncertain or inadequate evidence-based diagnoses. Expenditures for off-label indications were 17.1% of expenditures for rituximab usage.
conclusionThe frequent use of rituximab for off-label indications should lead to improved postapproval surveillance of biologics by the US Food and Drug Administration, so that use can be adequately studied. This will also facilitate improved regulatory mechanisms to ensure evidence-based use.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.